As of March 24, 2021, the U.S. Government, in coordination with Eli Lilly and Company, has stopped the distribution of bamlanivimab alone in the United States. Direct ordering for bamlanivimab and etesevimab together will continue as normal. Sites with sufficient bamlanivimab on hand can order etesevimab alone to pair with existing bamlanivimab inventory.
It is important to remember that etesevimab cannot be administered alone and should be administered together with bamlanivimab in accordance with the Emergency Use Authorization (EUA). For information on the EUA for the administration of bamlanivimab and etesevimab together, click here.
Ensuring the authenticity of bamlanivimab
Eli Lilly and Company is committed to patient safety and ensuring that people have accurate information about investigational bamlanivimab, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate bamlanivimab to protect patients from products that might be dangerous and lead to serious and life-threatening harm.
If you believe you have purchased or have been offered counterfeit bamlanivimab, please report it to the FDA.